Aidport Sp. z o.o. — Clinical Trial Site

72 Registered trials

39 Currently recruiting

Organisation

Aidport Sp. z o.o.

Location

Skorzewo, Poland

Identifier

ORG-100049010

Address

Ul Ksiedza Stanisława Kozierowskiego 24, 60-185, Poland

Departments

-
#2303 : Onkologia Kliniczna
#9004: oncology
2803 : NA
4102
AIDPORT
Aidport Sp z o o
Aidport sp z o.o.
AIDPORT Sp. z o.o.
AIDPORT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Gynaecology
Hematology
N/A
NA
Oncology
PL30003: Hematooncology
Poradnia Onkologiczna

Clinical trials at this site (72)

Search interface

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Newly Diagnosed Advanced Stage Follicular Lymphoma 4 2024-10-10
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize… Ended

2023-507527-28-00 Recurrent vulvovaginal candidiasis 7 2024-09-16
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymph 5 2024-09-03
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 High-risk Large B-cell Lymphoma 5 2024-07-31
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL Ended

2023-509258-71-00 relapsed or refractory B‑cell non-Hodgkin lymphomas 1 2024-07-24
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 DIFFUSE LARGE B CELL LYMPHOMA 4 2023-01-24
This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended

2023-505628-67-00 Relapsed and Refractory Follicular Lymphoma 5 2022-10-28
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL Ended

2023-504187-42-00 Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leuk 1 2022-09-12
A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Ended

2023-507993-42-00 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ( 9 2022-03-17
A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended

2024-511599-33-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-12-22
MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended

2023-509208-14-00 MULTIPLE MYELOMA 5 2021-09-28
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects… Ended

2023-506094-35-00 Newly diagnosed aggressive B-cell lymphoma (a-BCL) 3 2021-09-17
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2021-03-24
A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended

2023-507695-52-00 Mantle cell lymphoma 5 2021-03-05
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Chronic Lymphocytic Leukemia 9 2020-11-16
A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended

2023-508759-38-00 Relapsed/Refractory B-cell Malignancies 1 2025-06-04
A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended

2024-515410-41-00 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder 9 2025-04-01
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom… Ended

2024-512848-30-00 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER 4 2024-11-12